3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Stomatitis
2
Mucositis
2
Mouth Neoplasms
2
Head and Neck Neoplasms
2
Neuroendocrine Tumors
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
6
Radiotherapy, Intensity-Modulated
4
Saline Solution
3
Injections
3
golotimod
2
avasopasem manganese
2
Water
2
Vitamin B 12
2
Standard of Care
2
RRx-001
2
Practice Guidelines as Topic
2
Gentamicins
2
Fibroblast Growth Factor 7
2
FGF20 protein, human
2
Drug Therapy
2
samital
1
regramostim
1
peppermint oil
1
meclocycline
1
hydrated silica gel-based toothpaste
1
holy basil leaf extract
1
cobiprostone
1
clazakizumab
1
calcium phosphate
1
brilacidin
1
anise oil
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Stomatitis
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts